Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2005-05-31
2005-05-31
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S133100, C424S141100, C424S143100, C424S144100, C424S152100, C424S172100, C424S173100, C530S387100, C530S387300, C530S388100, C530S388200, C530S388220, C530S388700, C530S388730
Reexamination Certificate
active
06899879
ABSTRACT:
Methods for preventing or treating an IgE-mediated allergic disease in a patient are presented, the methods comprising administration of a monoclonal antibody capable of binding to a human CD40 antigen located on the surface of a human B cell, wherein binding of the antibody to the CD40 antigen prevents the growth or differentiation of the B cell. Monoclonal antibodies useful in these methods, and epitopes immunoreactive with such monoclonal antibodies are also presented.
REFERENCES:
patent: 4355023 (1982-10-01), Ehrlich et al.
patent: 4689299 (1987-08-01), Insel et al.
patent: 4886796 (1989-12-01), Eichner et al.
patent: 4923872 (1990-05-01), Kostlan et al.
patent: 5068223 (1991-11-01), Lipsky et al.
patent: 5100899 (1992-03-01), Calne
patent: 5182368 (1993-01-01), Ledbetter et al.
patent: 5674492 (1997-10-01), Armitage et al.
patent: 5677165 (1997-10-01), de Boer et al.
patent: 5801227 (1998-09-01), Fanslow et al.
patent: 5874082 (1999-02-01), de Boer
patent: 5916560 (1999-06-01), Larsen et al.
patent: 6004552 (1999-12-01), de Boer et al.
patent: 0 434 879 (1991-07-01), None
patent: 0 555 880 (1993-08-01), None
patent: 0 585 943 (1998-02-01), None
patent: WO 90/07861 (1990-07-01), None
patent: WO 92/00092 (1992-01-01), None
patent: WO 94/04570 (1992-03-01), None
patent: WO 93/08207 (1993-04-01), None
patent: WO 93/11794 (1993-06-01), None
patent: WO 94/01457 (1994-01-01), None
patent: WO 94/01547 (1994-01-01), None
patent: WO 95/09653 (1995-04-01), None
patent: WO 00/16801 (2000-03-01), None
patent: WO 01/24823 (2001-04-01), None
patent: WO 01/34649 (2001-05-01), None
patent: WO 01/83755 (2001-11-01), None
The Merck Manual of Diagnosis and Therapy 16THEdition, Edited by Berkow et al., Merck Research Laboratories, Rathway NJ 1992, p. 316 Only.*
Armitage, et al.,Molecular and Biological Characterization of a Murine Ligand for CD40, Nature 357:80-82 (May 7, 1992).
Banchereau, et al.Long-Term Human B Cell Lines Dependent on Interleukin-4 and Antibody to CD40, Science 251:70-72 (Jan. 4, 1991).
Banchereau, et al.,Growing Human B Lymphocytes in the CD40 System, Nature 353:678-679 (Oct. 17, 1991).
Chothia, et al.,Canonical Structures for the Hypervariable Regions of Immunoglobulins, J. Mol. Biol. 196:901-917 (1987).
Claassen, et al.,Mononuclear cells from patients with the hyper-IgE syndrome produce with IgE when they are stimulated with recombinant human interleukin-4, J. Allergy Clin., Immunol. 88:713-721 (1994).
Clark, et al.,Activation of Human B Cells Mediated Through Two Distinct Cell Surface Differentiation Antigens, Bp35 and Bp50, Proc. Natl. Acad. Sci. USA 83:4494-4498 (Jun. 1986).
Clark, et al.,Association Between IL-6 and CD40 Signaling IL0-6 Induces Phosphorylation of CD40 Receptors, J. Immunol. 145(5):1400-1406 (Sep. 1, 1990).
Cosimi, et al.,Use of Monoclonal Antibodies to T-Cell Subsets for Immunologic Monitoring and Treatment in Recipients of Renal Allografts, N. Eng. J. Med. 305(6):308-313 (Aug. 6, 1981).
de Boer, et al.,Generation of Monoclonal Antibodies to Human Lymphocyte Cell Surface Antigens Using Insect Cells Expressing Recombinant Proteins, J. Immunol., Meth. 152:15-23 (1992).
DeFranco, et al.,Separate Control of B Lymphocyte Early Activation and Proliferation in Response to Anti-IgM Antibodies, The Journal of Immunology 135(1)87-94 (Jul. 1985).
DiSanto, et al.,Generation of anti-human CD8β-specific antibodies using transfectants expressing mixed-species CD8 heterodimers, J. Immunol. Methods 141:123-131 (1991).
Edgington,How Sweet it is : Selectin-Mediating Drugs, Biotechnology 10:383-389 (1992).
Fanslow, et al.,CD40 MABS M2 and M3 inhibit CD40L Binding and Function, Tissue Antigens 42(3):304 (Oct. 1993).
Francisco, et al.,Activity of a Single-Chain Immunotoxin that Selectively Kills Lymphoma and Other B-Lineage Cells Expressing the CD40 Antigen, Cancer Research 55:3099-3104 (Jul. 15, 1995).
Freedman, et al.,B7, A B Cell-Restricted Antigen that Identifies Preactivated B Cells, The Journal of Immunology 139(10):3260-3267 (Nov. 15, 1997).
Garrone, et al.,mAb 104, a new monoclonal antibody, recognizes the B7 antigen that is expressed on activated B cells and HTLV-1 transformed T cells, Immunology 69:531-535 (1990).
Gascan, et al.,Anti-CD40 Monoclonal Antibodies or CD4+T Cell Clones andIL-4 Induce IgG4 and IgE Switching in Purified Human B Cells Vai Different Signaling Pathways, The Journal of Immunology 147(1):8-13 (Jul. 1, 1991.
Gauchat, et al.,Modulation of IL-4 induced germline ∈ RNA synthesis in human B cells by tumor necrosis factor-α, anto-CD40 monoclonal antibodies or transforming growth factor-β correlates with levels of IgE production, International Immunology 4(3):397-406 (1991).
Golub,Immunology a Synthesis, Sinauer Assoc. Inc., Sunderland, MA. pp 19-20 (1987).
Gordon, et al.,Resting B Lymphocytes can be Triggered Directly Through the CDw40(Bp50)Antigen, A Comparison with IL-4-Mediated Signaling, The Journal of Immunology 140(5):1425-1430 (Mar. 1, 1988).
Gray, et al.,Memory B Cell Development butnot Germinal Center Formation is Impaired by In Vivo Blockade of CD40-CD40 Ligand Interaction, J. Exp. Med. 180:141-155 (Jul., 1994).
Gruber, et al.,Anti-CD45 Inhibition of Human B Cell Proliferation Depends on the Nature of Activation Signals and the State of B Cell Activation, J. Immunol. 142(12):4144-4152 (Jun. 15, 1989).
Harris, et al.,Therapeutic antibodies-the coming of age, Tibtech 11:42-44 (Feb. 1993).
Hartog, et al.,Generation of a humanized anti-CD40 mab for treatment of autoimmune diseases. Immunotechnology 2(4):299 (Nov. 1996) (abstract).
Jabara, et al.,CD40 and IgE: Synergism between Anti-CD40 Monoclonal Antibody and Interleukin 4 in the Induction of IgE Synthesis by Highly Purified Human B Cells, J. Exp. Med. 172:1861-1864 (Dec. 1990).
June, et al.,Role of the CD28 Receptor in T-cell activation, Immunology Today 11(6):211-216 (1990).
Jung, et al.,Selective Inhibition of Growth Factor-Dependent Human B Cell Proliferation by Monoclonal Antibody AB1 to an Antigen Expressed by Activated B Cells, J. Exp. Med 160:1919-1924 (Dec. 1984).
Kabat, et al.,Sequences of Proteins of Immunological Interest, Tabulation and Analysis of Amino Acid and Nucleic Acid Sequences of Precursors, V-Regions, CO-Regions, J-Chain, β2-Microglobulins, Major Histocompatibility Antigens, Thy-1, Complement, c-Reactive Protein, Thymopoietin, Post-gamma Globulin, and α2-Macroglobulin, sponsored through Contract NO1-RR-8-2118 by components of the National Institutes of Health, Bethesda, MD 20205 (1983).
Kahan,Immunosuppressive therapy, Curr. Opin Immunology 4:553-560 (1992).
Knight, et al.,The Immunogenicity of the 7E3 Murine Monoclonal FAB Antibody Fragment Variable Region is Dramatically Reduced in Humans by Substitution of Human for Murine constant Regions, Molecular Immunology 32(16):1271-1281 (1995).
Kriegler, et al.,A Novel Form of TNF/Cachectin is a Cell Surface Cytotoxic Trasmembrane Protein: Ramifications for the Complex Physiology of TNF, Cell 53:45-53 (1988).
Kwekkeboom, et al.,CD40 plays an essential role in the activation of human B Cells by Murine EL4B5 cells, Immunology 79:439-444 (1993).
Lane, et al.,Activated human T cells express a ligand for the human B Cell-associated antigen CD40 which participates in T cell-dependent activation of B lymphocytes, Eur. J. Immunol 22:2573-2578 (1992).
Ledman, et al.,Anti-CD40 Monoclonal Antibody Blocks the Contract Dependent T Helper Signal Mediated by 5C8 Ag., Clinical Research 40:154A (1992).
Linsley, et al.,CTLA-4 is a Second Receptor for the B Cell Activation Antigen B7, J. Exp. Med. 174:561-569 (Sep. 1991).
Muraguchi, et al.,Sequential Requirements for Cell Cycle Progression of Resting Human B Cells after Activation by Anti-Ig, The Journal of Immunology 132(1):176-180 (1984).
Noelle, et al.,T Helper Cells, Current Opinion in Immunology 4:333-337 (1992).
Padlan, et al.,A Possible Procedure for Reducing the Immunogenicity of Antibody Variable Domains While Preserving Their Ligand-Binding Properties, Molecular Immunology 28(4/5):489-498 (1991).
Paul (ED) Fundamental Immunology Raven Press NY
Conroy Leah B
de Boer Mark
Alexander Lisa E.
Chiron Corporation
Gambel Phillip
Harbin Alisa A.
Henry Leslie T.
LandOfFree
Method for treating an IgE-mediated disease in a patient... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating an IgE-mediated disease in a patient..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating an IgE-mediated disease in a patient... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3384359